The present invention relates to a compound of the general formula (I) [wherein Ar1 is a 5- or 6-membered heteroaryl group containing 1, 2 or 3 heteroatoms selected from phenyl or N, S or O. Wherein the N-heteroatom in the heteroaryl group can be oxidized to N +-(O-), R1 is lower alkyl, halogen, cyano, or cycloalkyl, and Ar2 is A 5- or 6-membered heteroaryl group containing 1, 2, 3, or 4 heteroatoms selected from N, S, or O, wherein the N-heteroatom in the heteroaryl group is N + Can be oxidized to-(O-) or is benzo [b] thiophenyl and R2 is substituted with hydrogen, lower alkyl, halogen, cyano, hydroxyl substituted lower alkyl, halogen Lower alkyl substituted with amino, lower alkyl substituted with alkoxy, lower alkyl substituted with amide, or cycloalkyl, and X is CH or N And n is 1 or 2, and m is 1 or 2], and pharmaceutically acceptable salts, racemic mixtures thereof, or the like It relates to the corresponding enantiomer and / or its optical isomer and / or its stereoisomer. This compound is a CNS disease, substance abuse, alcohol and drug addiction, obsessive compulsive disorder, cognitive impairment, bipolar disorder, mood disorder, major depression, treatment resistance associated with positive (psychotic) and negative symptoms of schizophrenia Depression, anxiety disorder, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disorder, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, muscle atrophy It can be used for the treatment of lateral sclerosis, epilepsy, arthritis effects, autoimmune diseases, viral and fungal infections, cardiovascular diseases, ophthalmic and inflammatory retinal diseases, and balance disorders.本発明は、一般式（Ｉ）［式中、Ａｒ１は、フェニル又は、Ｎ、Ｓ、もしくはＯから選択される１、２、もしくは３つのヘテロ原子を含有する５もしくは６員のヘテロアリール基であり、ここで、ヘテロアリール基中のＮ－ヘテロ原子は、Ｎ＋－（Ｏ－）に酸化されていることができ、Ｒ１は、低級アルキル、ハロゲン、シアノ、又はシクロアルキルであり、Ａｒ２は、Ｎ、Ｓ、又はＯから選択される１、２、３、又は４つのヘテロ原子を含有する５又は６員のヘテロアリール基であり、こ
